1
|
Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy. Molecules 2022; 27:molecules27175607. [PMID: 36080373 PMCID: PMC9458026 DOI: 10.3390/molecules27175607] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 08/24/2022] [Accepted: 08/24/2022] [Indexed: 12/24/2022] Open
Abstract
Messenger RNA (mRNA) is being developed by researchers as a novel drug for the treatment or prevention of many diseases. However, to enable mRNA to fully exploit its effects in vivo, researchers need to develop safer and more effective mRNA delivery systems that improve mRNA stability and enhance the ability of cells to take up and release mRNA. To date, lipid nanoparticles are promising nanodrug carriers for tumor therapy, which can significantly improve the immunotherapeutic effects of conventional drugs by modulating mRNA delivery, and have attracted widespread interest in the biomedical field. This review focuses on the delivery of mRNA by lipid nanoparticles for cancer treatment. We summarize some common tumor immunotherapy and mRNA delivery strategies, describe the clinical advantages of lipid nanoparticles for mRNA delivery, and provide an outlook on the current challenges and future developments of this technology.
Collapse
|
2
|
Hamieh M, Chatillon JF, Dupel E, Bayeux F, Fauquembergue E, Maby P, Drouet A, Duval-Modeste AB, Adriouch S, Boyer O, Latouche JB. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy. Front Immunol 2021; 12:674276. [PMID: 34566953 PMCID: PMC8456028 DOI: 10.3389/fimmu.2021.674276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Accepted: 08/13/2021] [Indexed: 02/03/2023] Open
Abstract
Adoptive immunotherapy based on the transfer of anti-tumor cytotoxic T lymphocytes (CTLs) is a promising strategy to cure cancers. However, rapid expansion of numerous highly functional CTLs with long-lived features remains a challenge. Here, we constructed NIH/3T3 mouse fibroblast-based artificial antigen presenting cells (AAPCs) and precisely evaluated their ability to circumvent this difficulty. These AAPCs stably express the essential molecules involved in CTL activation in the HLA-A*0201 context and an immunogenic HLA-A*0201 restricted analogue peptide derived from MART-1, an auto-antigen overexpressed in melanoma. Using these AAPCs and pentamer-based magnetic bead-sorting, we defined, in a preclinical setting, the optimal conditions to expand pure MART-1-specific CTLs. Numerous highly purified MART-1-specific CTLs were rapidly obtained from healthy donors and melanoma patients. Both TCR repertoire and CDR3 sequence analyses revealed that MART-1-specific CTL responses were similar to those reported in the literature and obtained with autologous or allogeneic presenting cells. These MART-1-specific CTLs were highly cytotoxic against HLA-A*0201+ MART-1+ tumor cells. Moreover, they harbored a suitable phenotype for immunotherapy, with effector memory, central memory and, most importantly, stem cell-like memory T cell features. Notably, the cells harboring stem cell-like memory phenotype features were capable of self-renewal and of differentiation into potent effector anti-tumor T cells. These "off-the-shelf" AAPCs represent a unique tool to rapidly and easily expand large numbers of long-lived highly functional pure specific CTLs with stem cell-like memory T cell properties, for the development of efficient adoptive immunotherapy strategies against cancers.
Collapse
Affiliation(s)
- Mohamad Hamieh
- Normandie University, UNIROUEN, Inserm U1245, Institute for Research and Innovation in Biomedecine (IRIB), Rouen, France
| | - Jean-François Chatillon
- Normandie University, UNIROUEN, Inserm U1234 - Pathophysiology, Autoimmunity, Neuromuscular diseases and regenerative THERapies (PANTHER), IRIB, Rouen, France
| | - Estelle Dupel
- Normandie University, UNIROUEN, Inserm U1245, Institute for Research and Innovation in Biomedecine (IRIB), Rouen, France
| | - Florence Bayeux
- Normandie University, UNIROUEN, Inserm U1234 - Pathophysiology, Autoimmunity, Neuromuscular diseases and regenerative THERapies (PANTHER), IRIB, Rouen, France
| | - Emilie Fauquembergue
- Normandie University, UNIROUEN, Inserm U1245, Institute for Research and Innovation in Biomedecine (IRIB), Rouen, France
| | - Pauline Maby
- Normandie University, UNIROUEN, Inserm U1245, Institute for Research and Innovation in Biomedecine (IRIB), Rouen, France
| | - Aurelie Drouet
- Normandie University, UNIROUEN, Inserm U1245, Institute for Research and Innovation in Biomedecine (IRIB), Rouen, France
| | | | - Sahil Adriouch
- Normandie University, UNIROUEN, Inserm U1234 - Pathophysiology, Autoimmunity, Neuromuscular diseases and regenerative THERapies (PANTHER), IRIB, Rouen, France
| | - Olivier Boyer
- Normandie University, UNIROUEN, Inserm U1234 - Pathophysiology, Autoimmunity, Neuromuscular diseases and regenerative THERapies (PANTHER), IRIB, Rouen, France.,Department of Immunology and Biotherapy, Rouen University Hospital, Rouen, France
| | - Jean-Baptiste Latouche
- Normandie University, UNIROUEN, Inserm U1245, Institute for Research and Innovation in Biomedecine (IRIB), Rouen, France.,Department of Genetics, Rouen University Hospital, Rouen, France
| |
Collapse
|
4
|
Muccioli M, Longstaff C, Benencia F. Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma. Immunotherapy 2012; 4:477-81. [PMID: 22642330 DOI: 10.2217/imt.12.39] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. It has been considered that, similar to what has been observed in the context of immunological responses towards microbes, CD4 help is indispensable for the development of a successful and long-lasting (memory) CD8 immune response. In the recent article, Côté et al. reported that, in a mouse model of melanoma, total ablation of CD4 help does not hamper the development of a specific antitumor memory CD8 response. In addition, ablation of CD4 was more successful than strategies to deplete CD25 Tregs in generating memory CD8 T cells. These data opens the door for therapies destined to induce effective antitumor immune responses by ablation of whole CD4 T-cell populations.
Collapse
Affiliation(s)
- Maria Muccioli
- Molecular & Cell Biology Program, Ohio University, OH, USA
| | | | | |
Collapse
|